The XRP price exploded from $0.5 in 2024 to over $3 in 2025. In the span of a few months, the cryptocurrency, which had been suppressed, made history and was onlyThe XRP price exploded from $0.5 in 2024 to over $3 in 2025. In the span of a few months, the cryptocurrency, which had been suppressed, made history and was only

Why XRP Is About To Experience A Legendary Next 3 Months

2026/01/08 01:00
3 min read
For feedback or concerns regarding this content, please contact us at crypto.news@mexc.com

The XRP price exploded from $0.5 in 2024 to over $3 in 2025. In the span of a few months, the cryptocurrency, which had been suppressed, made history and was only a few percentage points away from revisiting its all-time high. According to a crypto analyst, XRP may soon replicate its legendary 2017 rally, potentially reaching a new all-time high in the next three months. 

XRP To See Parabolic Rally In Three Months

Market expert @Cryptobilbuwoo0 has shared a bullish outlook on XRP, pointing to a familiar price structure that closely mirrors the 2017 market cycle. According to the analyst, XRP began its powerful breakout near $3.60 in 2017, then skyrocketed to its ATH around $3.84 in 2018.

Related Reading: Standard Chartered Analysts Predict 330% XRP Price Surge After This Happens

He pointed out that in 2017, once the price broke above the dotted support line, which represented a long rising diagonal trend on the chart, XRP reached its $3.6 target within a week. Notably, this move delivered gains of approximately 1,184.86%. Based on the rally’s speed and intensity, the analyst suggests that XRP could be poised for another sharp surge, claiming that investors’ lives could change dramatically over the next 2 to 3 months.

Notably, @Cryptobilbuwoo0’s chart analysis shows that XRP is already breaking out from a clearly defined base, having held above the same rising diagonal support line from 2017. At the same time, the breakout occurs as price reclaims the 52-week Exponential Moving Average (EMA), a level that previously marked the beginning of strong upside expansion for XRP. 

XRP

Fibonacci Extensions on the chart further highlight the 1.618 level as a key upside target, in line with the 2017 cycle peak structure. The chart also marks TP1 and TP2 zones, where the price paused briefly in 2017 before continuing higher. These shallow pullbacks were quickly bought, signaling strong trend control in the previous cycle. 

Current projections suggest a strong and sustained upward momentum following XRP’s breakout above the dotted support line. For its first target, price is expected to rally toward TP1 at $23.2, representing a massive 1,183.38% increase. Beyond this level, XRP is projected to continue its rally toward TP2 around $136.3, signaling a potentially historic upside. Remarkably, @Cryptobilbuwoo0’s chart suggests that all of these parabolic moves could unfold before the end of 2026.

Momentum Indicators Support Bullish XRP Forecast

XRP is currently trading above $2.2, up more than 21% in the past week. Given the cryptocurrency’s historically slow price movements, @Cryptobilbuwoo0’s forecast of a rise to $23.2 and then $136.3 has been met with skepticism within the crypto community. 

However, the analyst points to momentum indicators at the bottom of the price chart that support his bullish outlook. He showed that in 2017, XRP’s Relative Strength Index (RSI) hit oversold levels just before the price surged dramatically. A similar pattern is appearing in the current market, reinforcing his belief that the next 2 to 3 months could be parabolic.

XRP
Market Opportunity
XRP Logo
XRP Price(XRP)
$1.3663
$1.3663$1.3663
+0.72%
USD
XRP (XRP) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact crypto.news@mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Key Takeaways Vitalik Buterin wants Ethereum apps built to survive without developers, corporate servers, or trusted third parties Two major […] The post Vitalik
Share
Coindoo2026/03/07 15:49
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

The post Short-term profit-taking pushes Bitcoin back below key $70K level – What next? appeared on BitcoinEthereumNews.com. Bitcoin [BTC] rallied as high as $74
Share
BitcoinEthereumNews2026/03/07 16:09